Specimen Reference Sets

Organ Protocol ID Reference Set Title Cases Controls Total Participants Participant groups Specimen type Number of specimens Volume range, mL Specimens at NCI-F? Sequential samples? Follow-up data? Pathology? Image files available? Incidental cancer?
Breast 331 Benign Breast Disease 30 62 92 BBD that progressed to cancer
BBD controls
Tissue slides 9,256 "each" No, at Kansas N/A No Yes No Yes
Breast 121 Breast 262 570 832 Pre-diagnosis specimens
DCIS cases
Invasive cancer cases
LCIS cases
Benign→later cancer cases
Normal→later cancer cases
Benign Disease Atypia controls
Benign Disease non-Atypia controls
Normal controls
Serum 16,444 0.01-0.8 Yes No No Yes No Yes
Plasma 16,169 0.01-0.9
Ovarian & Breast 118 Cancers in women-BRSCW 441 95 536 Cases (pooled)
Controls (pooled)
Serum 105 sets 0.3 Yes No No No No No
Colon 251 Colon cancer 50 100 150 Serum 2,100 0.3 Yes No No No No No
Plasma 1,500 0.3
Urine 150 5
Liver 111 DCP/Liver Ref set Rapid set 50 50 100 Serum 1,329 0.01-0.5 Yes No No No No Yes
Plasma 731 0.2-0.5
Liver 111 DCP/Liver Ref set Validation set 427 432 871 Serum 10,815 0.01-1.0 Yes No No No No No
Plasma 5,090 0.2-0.5
Lung 115 Lung Ref Set A Phase II Validation (retrospective) 268 309 577 Serum 3,695 0.025-0.5 Yes No No No No No
Plasma 5,267 0.15-0.3
Lung 115 Lung Ref Set B (retrospective) 86 147 233 Plasma 3,846 0.025-0.375 Yes No No No No No
Lung 115 Lung Ref Set C (prospective) 159 195 354 Serum 6,430 0.015-0.2 Yes No No No No No
Plasma 6,787 0.01-0.175
Pancreas 185 Pancreatic cancer 100 155 255 Serum 4,847 0.1-0.8 Yes No No Yes No No
Plasma 3,006 0.2-0.8
Prostate 274 Prostate cancer (from PCA3) 341 559 900 Serum 16,778 0.075-0.5 Yes No No No No Yes
Bufy coat 864 0.05-0.5
Whole urine 771 1.2-5.0
EDTA plasma 13,137 0.1
Sediment/RNALater 738 0.035-1.5
Sediment/PBS 486 0.01-0.4
Supernatant 1,493 2.5-50
PAXGene 1,716 "tubes"
Pancreas 342 Panc Cyst 48 270 318 Serum 16,958 0.1-0.3 Yes No No No No Yes
EDTA plasma 8,605 0.1-0.3
EUS Cystic Fluid 5,538 0.05-0.1
Surgical Cystic Fluid 4,599 0.1-0.6

General Documents for Reference Sets

EDRN Guidelines
Application Form for EDRN Reference Sets

Ovarian & Breast Cancer Reference Sets

Biomarker Reference Sets for Cancers in Women (BRSCW) (PDF)
Description of pooled reference sets for ovarian and breast cancer serum specimens
BRSCW Application Form

Breast Cancer Reference Sets

Breast Reference Set Summary (PDF)
Breast Reference Set Protocol (PDF)
Breast Reference Set Participant and Clinical Forms (PDF)
Application Form for EDRN Reference Sets

EDRN Benign Breast Disease Tissue Resource (BBD)

BBD Reference Set Summary Document (PDF)
Benign Breast Disease Application (PDF)
SOP For Selection of Benign Breast Disease Project

Lung Cancer Reference Sets

Lung Cancer Reference Set Documentation (PDF)
The goal of the NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) is to develop the requisite sample resources to pre-validate serum/plasma biomarkers for the early diagnosis of lung cancer.
Application Form for EDRN Reference Sets

Colon Cancer Reference Set

Colon Cancer Reference Set Description (PDF)
Application Form for EDRN Reference Sets

Prostate Cancer Reference Sets

Prostate Cancer Reference Set Description (PDF)
One of the goals of the EDRN Genitourinary (GU) Collaborative Group is the establishment of a biologic sample set on men prior to prostate biopsy, in association with clinical information and common data elements appropriate for evaluation of risk and prognosis of prostate cancer.
Application Form for EDRN Reference Sets

PCA3 Validation Study and Urinary Reference Set

Liver (Hepatocellular Carcinoma) Reference Set

Hepatocellular Carcinoma Reference Set Description (PDF)

Application Form for EDRN Reference Sets

Pancreatic Standard Specimen Reference Set

Pancreatic Cancer Reference Set Access Information (PDF)
Application Form for EDRN Reference Sets